Patent ID: 8748464

Claim:
A method of treating chronic immune hyperactivity in an individual, the method comprising administering to an individual having chronic immune hyperactivity an effective amount of a SIRT1 activator, wherein the SIRT1 activator is a compound of the formula: or a salt thereof, wherein R 19 is selected from: wherein: each Z 10 , Z 11 , Z 12 and Z 13 is independently selected from N, CR 20 or CR 1 ′; and each Z 14 , Z 15 and Z 16 is independently selected from N, NR 1 ′, S, O, CR 20 , or CR 1 ′, wherein: zero to two of Z 10 , Z 11 , Z 12 or Z 13 are N; at least one of Z 14 , Z 15 and Z 16 is N, NR 1 ′, S or O; zero to one of Z 14 , Z 15 and Z 16 is S or O; zero to two of Z 14 , Z 15 and Z 16 is N or NR 1 ′; zero to one R 30 is a solubilizing group; and zero to one R 1 ′ is an optionally substituted C 1 -C 3 straight or branched alkyl; each R 20 is independently selected from H or a solubilizing group; R 21 is selected from —NR 1 ′—C(O)—, —NR 1 ′—S(O) 2 —, —NR 1 ′—C(O)—NR 1 ′—, —NR 1 ′—C(S)—NR 1 ′—NR 1 ′—C(S)— NR 1 ′—CR 1 ′R 1 ′—, —NR 1 ′—C(O)—CR 1 ′R 1 ′—NR 1 ′—, —NR 1 ′—C(═NR 1 ′)—NR 1 ′—, —C(O)—NR 1 ′—C(O)—NR 1 ′—, —CR 1 ′R 1 ′—, —NR 1 ′—C(O)—C(O)—CR 1 ′═CR 1 ′—, —NR 1 ′—S(O) 2 —NR 1 ′–—NR 1 ′—C(O)—NR 1 ′—S(O) 2 —, —NR 1 ′—CR 1 ′R 1 ′—C(O)—NR 1 ′—, —CR 1 ′R 1 ′—C(O)—NR 1 ′—, —NR 1 ′—C(O)—CR 1 ′═CR 1 ′—CR 1 ′R 1 ′—, —NR 1 ′—C(═N—CN)—NR 1 ′—, —NR 1 ′—C(O)—CR 1 ′R 1 ′—O—, —NR 1 ′—C(O)—CR 1 ′R 1 —CR 1 ′R 1 ′—O—, —NR 1 ′—S(O) 2 —CR 1 ′R 1 ′—, —NR 1 ′—S(O) 2 —CR 1 ′R 1 ′—CR 1 ′R 1 ′—, —NR 1 ′— C(O)—CR 1 ′R 1 ′—; —NR 1 ′—C(O)—CR 1 ′R′ 1 —CR 1 ′R′ 1 —, —NR 1 ′—C(S)—NR 1 ′—CR 1 ′R′ 1 —CR 1 ′R′ 1 —, —NR 1 ′—C(O)—O—, wherein each R 1 ′ is independently selected from H or optionally substituted C 1 -C 3 straight or branched alkyl; and R 31 is selected from an optionally substituted monocyclic or bicyclic aryl, or an optionally substituted monocyclic or bicyclic heteroaryl, wherein the chronic immune hyperactivity results from an immunodeficiency virus infection.